A drug commonly used to slow bleeding during heart surgery increases a patient's risk of dying during the next 5 years, a new study suggests.
U.S. heart surgeons have used the drug, called aprotinin, for 14 years. But last year, researchers reported that people receiving it had heightened risks of kidney problems, heart attack, and stroke. Those findings prompted the U.S. Food and Drug Administration to change the labeling on aprotinin to limit its use to coronary-bypass surgery patients at high risk of blood loss.
Note: To comment, Science News subscribing members must now establish a separate login relationship with Disqus. Click the Disqus icon below, enter your e-mail and click “forgot password” to reset your password. You may also log into Disqus using Facebook, Twitter or Google.